192 related articles for article (PubMed ID: 26221874)
1. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Chesney J; Clark J; Lanceta L; Trent JO; Telang S
Oncotarget; 2015 Jul; 6(20):18001-11. PubMed ID: 26221874
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem B; Telang S; Clem A; Yalcin A; Meier J; Simmons A; Rasku MA; Arumugam S; Dean WL; Eaton J; Lane A; Trent JO; Chesney J
Mol Cancer Ther; 2008 Jan; 7(1):110-20. PubMed ID: 18202014
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
4. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Chesney J; Clark J; Klarer AC; Imbert-Fernandez Y; Lane AN; Telang S
Oncotarget; 2014 Aug; 5(16):6670-86. PubMed ID: 25115398
[TBL] [Abstract][Full Text] [Related]
5. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Ros S; Flöter J; Kaymak I; Da Costa C; Houddane A; Dubuis S; Griffiths B; Mitter R; Walz S; Blake S; Behrens A; Brindle KM; Zamboni N; Rider MH; Schulze A
Oncogene; 2017 Jun; 36(23):3287-3299. PubMed ID: 28092678
[TBL] [Abstract][Full Text] [Related]
6. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Clem BF; O'Neal J; Tapolsky G; Clem AL; Imbert-Fernandez Y; Kerr DA; Klarer AC; Redman R; Miller DM; Trent JO; Telang S; Chesney J
Mol Cancer Ther; 2013 Aug; 12(8):1461-70. PubMed ID: 23674815
[TBL] [Abstract][Full Text] [Related]
7. Coordinated expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 and heme oxygenase 2: evidence for a regulatory link between glycolysis and heme catabolism.
Li B; Takeda K; Ishikawa K; Yoshizawa M; Sato M; Shibahara S; Furuyama K
Tohoku J Exp Med; 2012 Sep; 228(1):27-41. PubMed ID: 22892400
[TBL] [Abstract][Full Text] [Related]
8. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
9. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B
Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771
[TBL] [Abstract][Full Text] [Related]
10. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Gao R; Li D; Xun J; Zhou W; Li J; Wang J; Liu C; Li X; Shen W; Qiao H; Stupack DG; Luo N
Theranostics; 2018; 8(22):6248-6262. PubMed ID: 30613295
[TBL] [Abstract][Full Text] [Related]
11. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Ros S; Santos CR; Moco S; Baenke F; Kelly G; Howell M; Zamboni N; Schulze A
Cancer Discov; 2012 Apr; 2(4):328-43. PubMed ID: 22576210
[TBL] [Abstract][Full Text] [Related]
12. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
13. Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes.
Houddane A; Bultot L; Novellasdemunt L; Johanns M; Gueuning MA; Vertommen D; Coulie PG; Bartrons R; Hue L; Rider MH
Cell Signal; 2017 Jun; 34():23-37. PubMed ID: 28235572
[TBL] [Abstract][Full Text] [Related]
14. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Dasgupta S; Rajapakshe K; Zhu B; Nikolai BC; Yi P; Putluri N; Choi JM; Jung SY; Coarfa C; Westbrook TF; Zhang XH; Foulds CE; Tsai SY; Tsai MJ; O'Malley BW
Nature; 2018 Apr; 556(7700):249-254. PubMed ID: 29615789
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives.
Zhang G; Ye X; Ji D; Zhang H; Sun F; Shang C; Zhang Y; Wu E; Wang F; Wu F; Tian H; Liu X; Chen L; Liu K; Wang Y; Liu H; Zhang W; Guan Y; Wang Q; Zhao X; Wan X
Oncotarget; 2014 Sep; 5(18):8528-43. PubMed ID: 25138052
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T
Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917
[TBL] [Abstract][Full Text] [Related]
17. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.
Yalcin A; Telang S; Clem B; Chesney J
Exp Mol Pathol; 2009 Jun; 86(3):174-9. PubMed ID: 19454274
[TBL] [Abstract][Full Text] [Related]
18. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Chowdhury N; Vhora I; Patel K; Doddapaneni R; Mondal A; Singh M
Pharm Res; 2017 Nov; 34(11):2371-2384. PubMed ID: 28875330
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Brooke DG; van Dam EM; Watts CK; Khoury A; Dziadek MA; Brooks H; Graham LJ; Flanagan JU; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):1029-39. PubMed ID: 24398380
[TBL] [Abstract][Full Text] [Related]
20. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
